[A21-63] Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2021
Project no.: A21-63
Commission: Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
Indication:
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older
Result of dossier assessment:
Added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.